On January 8, 2001, Millennium Pharmaceuticals, Inc., together with its wholly owned subsidiary Millennium Predictive Medicine, Inc., and Roche Diagnostics GmbH, a division of the Roche Group (Swiss Exchange: ROCZ.S), announced that they had entered into a collaborative research agreement that will focus on the development of diagnostic products for rheumatoid arthritis. The research will apply Millennium's advanced proteomics technologies and represents an expansion of Millennium's DiagnomicTM product development and personalized medicine initiatives into the area of rheumatoid arthritis. For Roche, the alliance provides an opportunity to further strengthen its proteomics research program to develop novel diagnostics. Under the terms of the three-year alliance, Roche obtains certain research and development rights to select diagnostic markers and related intellectual property developed by Millennium in the area of rheumatoid arthritis and Millennium receives a licensing fee, funding for research, milestone payments and royalties. Diagnostic products resulting from the alliance will be brought to market by Roche.
Hale and Dorr's Life Sciences Group served as counsel to Millennium in the negotiation of both agreements.